Onco Wiki / Regimen

Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 4489/4490)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

ComponentsNone declared
IDREG-CODOX-M-IVAC
TypeRegimen
Statuspending_clinical_signoff
DiseasesNone declared
SourcesSRC-EVIQ-BURKITT-CODOX-4489 SRC-EVIQ-BURKITT-IVAC-4490 SRC-EVIQ-BURKITT-OVERVIEW-3727 SRC-EVIQ-CODOX-PATIENT-4489 SRC-EVIQ-IVAC-PATIENT-4490 SRC-EVIQ-MOUTH-PATIENT-3099 SRC-EVIQ-TLS-108 SRC-NCCN-BCELL-2025

Notes

Scoped reference schedule repair based on eviQ 4489 v1 and 4490 v2, for high-risk Burkitt WITHOUT proven CNS disease. This is not original Magrath or LMB and not a universal Burkitt/CNS prescription. The indication now requires explicit high-risk and CNS-negative confirmation. Risk classification, broader eligibility, ranking and other protocol variants still require separate audits. Age, fitness, efficacy, availability and patient watchpoints are not validated by this repair. Mesna schedules may vary by institution. Intrathecal procedures must remain separate from IV drug administration; vincristine must NEVER be administered intrathecally.

Used By

Indication

Monitoring